Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8270187 | 0.98 | CYP4F2 (0.59) | CYP4F2CYP4A11NPSR1MAPTCYP2C19 | |
| SCHEMBL3952155 | 0.95 | CYP4F2 (0.56) | CYP4F2CYP4A11NPSR1MAPTCYP2C19 | |
| SCHEMBL1503918 | 0.91 | — | — | |
| SCHEMBL17155 | 0.82 | CYP4F2 (0.56) | CYP4F2CYP4A11NPSR1MAPTCYP2C19 | |
| SCHEMBL4294309 | 0.81 | CYP4F2 (0.43) | CYP4F2CYP4A11NPSR1MAPTKMT2A | |
| SCHEMBL2028459 | 0.81 | CYP4F2 (0.43) | CYP4F2CYP4A11NPSR1CYP2C19CYP3A4 | |
| SCHEMBL8278881 | 0.81 | CYP4F2 (0.71) | CYP4F2CYP4A11NPSR1MAPTCYP2C19 | |
| SCHEMBL8395342 | 0.80 | CYP4F2 (0.55) | CYP4F2CYP4A11NPSR1MAPTCYP2C19 | |
| SCHEMBL3541279 | 0.80 | CYP4F2 (0.55) | CYP4F2CYP4A11NPSR1MAPTCYP2C19 | |
| SCHEMBL1969086 | 0.80 | CYP4F2 (0.55) | CYP4F2CYP4A11NPSR1MAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025031923-A1 | IMIDAZO[4,5-D]PYRIDAZINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS | SANOFI (FR) | 2025-02-13 | — | — | WO | disclosed |
| US-8816090-B2 | Benzisoxazole derivatives | PFIZER INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1856114-B1 | BENZISOXAZOLE DERIVATIVES | PFIZER (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8759365-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-8759365-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-8759365-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| CN-101910150-B | 4-benzylamino-1-carboxyacylpiperidine derivatives as CETP inhibitors useful in the treatment of diseases such as hyperlipidemia or arteriosclerosis | NOVARTIS AG | 2013-09-18 | — | — | CN | disclosed |
| CN-101878199-B | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis | NOVARTIS AG | 2013-09-18 | — | — | CN | disclosed |
| EP-2463282-B1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | NOVARTIS AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| WO-2009071509-A1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071509-A1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20080207690-A1 | Benzisoxazole Derivatives | RAQUALIA PHARMA INC. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1856114-A1 | BENZISOXAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090224-A1 | BENZISOXAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CYP4F2 492/4885CYP4A11 105/4885NPSR1 1460/4885 |
| US-20080207690-A1 | Benzisoxazole Derivatives | BRS3, MRGPRX4, HTR4 | CYP4F2 681/4885CYP4A11 451/4885NPSR1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.